Safety of Two Trivalent Influenza Vaccines Evaluated in Children and Adolescents 4 to 17 Years of Age
NCT01857206
Completed
Evaluate safety and tolerability of TIVa or TIVb vaccine in healthy children and adolescents 4 to 17 years of age.
Gender:
ALL
Ages:
Between 4 years and 17 years
Trial Updated:
11/18/2014
Locations: 311, Novartis Investigational Site, Fremont, Nebraska
Conditions: Influenza, Fever
Register for Updates
A Study to Evaluate Safety and Immune Response of Novartis Meningococcal ACWY Vaccine In Infants
NCT00474526
Completed
This study will evaluate the safety and immune response of the Novartis Meningococcal ACWY conjugate vaccine when administered with routine infant vaccinations to healthy infants.
Gender:
ALL
Ages:
Between 2 months and 2 months
Trial Updated:
02/24/2014
Locations: Creighton University, Omaha, Nebraska +1 locations
Conditions: Meningitis, Meningococcal
Register for Updates
A Phase 4, Placebo-Controlled, Randomized Study to Evaluate the Immunogenicity and Safety of HPV and Tdap When Administered With MenACWY in Adolescents
NCT01424644
Completed
The main objective is to determine whether immune responses to Tdap (GlaxoSmithKline, Boostrix®) and HPV vaccine (Merck \& Co., Inc., Gardasil®) when administered concomitantly with MenACWY are comparable to responses elicited by these vaccines when given alone.
Gender:
ALL
Ages:
Between 11 years and 18 years
Trial Updated:
01/21/2014
Locations: Bellevue Family Practice, 2206 Longo Suite 201, Bellevue, Nebraska +2 locations
Conditions: Meningococcal Meningitis
Register for Updates
Vaccine Therapy Plus Radiation Therapy in Treating Patients With Non-small Cell Lung Cancer That Has Been Completely Removed in Surgery
NCT00006470
Completed
RATIONALE: Vaccines may make the body build an immune response to kill tumor cells. Radiation therapy uses high-energy x-rays to damage tumor cells. Combining these two treatments may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of combining vaccine therapy with radiation therapy in treating patients who have stage II or stage IIIA non-small cell lung cancer that has been completely removed in surgery.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/09/2013
Locations: CCOP - Missouri Valley Cancer Consortium, Omaha, Nebraska +2 locations
Conditions: Lung Cancer
Register for Updates
Vaccine Therapy in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer
NCT00003386
Terminated
RATIONALE: Vaccines made from tumor tissue may make the body build an immune response and kill tumor cells. PURPOSE: Phase II trial to study the effectiveness of vaccine therapy in treating patients who have stage III or stage IV ovarian epithelial cancer.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
04/10/2013
Locations: CCOP - Missouri Valley Cancer Consortium, Omaha, Nebraska
Conditions: Ovarian Cancer
Register for Updates
Multi-Year Study of Fluzone High-Dose Influenza Vaccine Compared With Fluzone® Vaccine in Adults Aged 65 Years and Older
NCT00976027
Terminated
The aim of this study is to determine the efficacy of Fluzone High Dose vaccine and that of Fluzone® vaccine in the elderly. Primary objective: To measure the efficacy of the vaccine, defined as the prevention of laboratory-confirmed influenza caused by viral types/subtypes that are antigenically similar to those contained in the respective annual vaccine formulations. Secondary objectives: * To compare the clinical efficacy of Fluzone High Dose vaccine with that of Fluzone® vaccine in elder... Read More
Gender:
ALL
Ages:
65 years and above
Trial Updated:
07/24/2012
Locations: Not set, Omaha, Nebraska
Conditions: Influenza
Register for Updates
NicVAX/Placebo as an Aid for Smoking Cessation
NCT00836199
Completed
The purpose of this study is to evaluate NicVAX as an aid to smoking cessation for long term abstinence.
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
05/08/2012
Locations: NicVAX Investigator, Omaha, Nebraska
Conditions: Smoking Cessation, Smoking, Tobacco Cessation
Register for Updates
A Second Study of NicVAX/Placebo as an Aid for Smoking Cessation
NCT01102114
Completed
The purpose of this study is to evaluate NicVAX as an aid to smoking cessation for long term abstinence.
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
05/08/2012
Locations: NicVAX Investigator, Omaha, Nebraska
Conditions: Smoking Cessation
Register for Updates
Title: Recombinant Plague Vaccine rF1V in Healthy Volunteers
NCT00332956
Completed
This Phase 2(a) clinical trial is designed as a dose-blinded, block-randomized, multi-center study to select a dosage and schedule of rF1V vaccine for further studies based on the immune response up to Day 210. Additional immunogenicity and safety/reactogenicity data will be collected through Day 540. Selection of dosage and schedule will be based on GMCs and seroconversion rates for anti-F1, anti-V and anti-rF1V antibody titers. Approximately 400 healthy adult volunteers will be enrolled (100 p... Read More
Gender:
ALL
Ages:
Between 18 years and 55 years
Trial Updated:
11/28/2011
Locations: Meridian clinical Research, LLC, Omaha, Nebraska
Conditions: Healthy Volunteers
Register for Updates
Tumor Cell Vaccine in Treating Patients With Advanced Cancer
NCT00002505
Completed
RATIONALE: Vaccines made from the patient's cancer cells may make the body build an immune response and kill their tumor cells. PURPOSE: Randomized phase II trial to study the effectiveness of autologous tumor cell vaccination plus immunologic adjuvant in treating patients who have metastatic cancer.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/10/2011
Locations: Bergan Mercy Medical Center, Omaha, Nebraska
Conditions: Unspecified Adult Solid Tumor, Protocol Specific
Register for Updates